DOCS
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Doximity, Inc. is a physician-focused technology company that operates a professional network for U.S. medical professionals. The platform serves registered members, including physicians, nurse practitioners, physician assistants, and medical students, providing tools for collaboration, career management, and clinical workflow. Its business segments include Marketing Solutions, which allows pharmaceutical manufacturers and health systems to target medical professionals; Hiring Solutions, which offers digital recruiting and staffing services through Curative Talent; and Workflow Solutions, which includes telehealth, on-call scheduling, digital fax, and AI tools. Key products within the Clinical AI Suite include Dialer for voice and video telehealth, Scribe for ambient AI note generation, and Ask for evidence-based clinical answers. The company serves customers primarily in the pharmaceutical and healthcare sectors across the United States.

Summarised from the company's own disclosures, fiscal year ended May 2026

Industry Internet Content & Information Homepage doximity.com
Sector Communication Services IR page investors.doximity.com
Tags
medical professional network, telehealth, clinical ai, physician marketing, medical recruiting, on-call scheduling, digital fax, ambient ai, clinical decision support, healthcare data, Dialer, Scribe, Ask, Curative Talent, Residency Navigator, Salary Map, Clinical AI Suite
Press page —

Metrics

Valuation  
Market cap $ 5.94B
Market cap (USD) $ 5.94B
P/E 46.92
PEG 2.32
P/BV 6.40
P/S 8.98
P/OCF 19.43
P/FCF 18.20
Dividend yield —
Turnover / mcap —
Returns  
ROE 19.3%
ROI 26.5%
ROIC 22.8%
Profit margin 30.4%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) 20.2%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 7
Quality score 23.5%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Revenue 644.863M 570.399M 475.422M 419.052M 343.548M
Net profit 196.051M 223.185M 147.582M 112.818M 154.783M
Free cash flow 326.458M 273.265M 183.949M 177.901M 124.663M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Share price 23.3 58.03 26.91 32.38 52.09
Price performance 12m -0.6 1.16 -0.17 -0.38 —

Filed figures

Figure Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (USD) — — 50.3M 81.1M 107M 101M 128M 145M
↳ YoY growth +61.1% +32.0% -5.3% +26.7% +12.8%
↳ 5y CAGR +23.5%
Lease liabilities (USD) — — 1.25M 1.09M 15.6M 14.5M 12.4M 10.2M
Cash and deposits (USD) 33.6M 48.4M 66.4M 113M 158M 96.8M 210M 219M
Intangible assets (USD) — — 9.6M 7.91M 31.8M 27.3M 23.1M 35.3M
Right-of-use assets (USD) — — 1.34M 1.09M 13.8M 12.3M 8.89M 7.14M
Cash flow detail
Operating cash flow (USD) — 26.2M 83M 127M 180M 184M 273M 326M
Purchases of property, plant and equipment (USD) — -285,000 -245,000 -1.91M -1.7M -147,000 0.00 0.00
Purchases of intangible assets (USD) — — — — — 0.00 0.00 -62,000
Change in receivables (cash effect) (USD) — -12M -20.5M -31M -26.2M 3.99M -27.2M -16.9M
Change in payables (cash effect) (USD) — 5.06M 7.29M 8.66M -195,000 8.33M -663,000 4.27M
Share buybacks (cash effect) (USD) — 0.00 -2.02M -2.7M -85.3M -281M -120M -432M
Income taxes paid (cash effect) (USD) — -1.24M -5.97M -206,000 -5.23M -51.3M -55.7M -21.8M
Share-based compensation (USD) — 2.35M 7.25M 31.4M 47.8M 51.1M 72.4M 122M
Operating cash flow before change in receivables (USD) — 38.2M 103M 158M 206M 180M 300M 343M
Free cash flow (OCF - PPE - intangibles) (USD) — 25.9M 82.7M 125M 178M 184M 273M 326M
Income detail
Research and development expense (USD) — 32.4M 43.9M 62.4M 80.2M 82M 93M 131M
↳ 5y CAGR +23.5% +24.4%
Total comprehensive income (USD) — 29.7M 50.2M 140M 114M 159M 227M 195M
Comprehensive income to owners (USD) — 29.7M 50.2M 140M 114M 159M 227M 195M
Reported May 27, 2022 May 27, 2022 May 27, 2022 May 27, 2022 May 26, 2023 May 19, 2026 May 19, 2026 May 19, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Total revenues of $174.5 million, up 4% year-over-year

Net income of $34.7 million, margin of 20%

Adjusted EBITDA of $88.9 million, margin of 51%

SAN FRANCISCO, Calif., November 5, 2026 -- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2027 second quarter ended September 30, 2026.

“We delivered another quarter of record engagement while investing heavily in AI and maintaining a 51% adjusted EBITDA margin,” said Jeff Tangney, co-founder and CEO of Doximity. “More than 190 health systems have now purchased our AI suite, and with UpToDate and DoseCheck, we’re extending our lead in distribution and trust.”

Fiscal 2027 Second Quarter Financial Highlights

All comparisons, unless otherwise noted, are to the three months ended September 30, 2025.

•Revenue: Revenue of $174.5 million, versus $168.5 million, an increase of 4% year-over-year.

•Net income and non-GAAP net income: Net income of $34.7 million, versus $62.1 million, representing a margin of 19.9%, versus 36.8%. Non-GAAP net income of $68.3 million, versus $90.0 million, representing a margin of 39.1%, versus 53.4%.

10/29/2026

AI models make mistakes in more than 1 in 50 drug dosing recommendations.

DoseCheck AI hardening reduces the error rate to near zero

SAN FRANCISCO--(BUSINESS WIRE)-- Doximity , Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, has launched DoseCheck, a free additional safety layer in Doximity Ask that instantly checks every AI-generated medication dosing claim against a structured drug database to reduce treatment errors and increase patient safety.

Doximity DoseCheck reduces AI drug dosing errors by more than 99%.

Doximity DoseCheck reduces AI drug dosing errors by more than 99%.

The probabilistic nature of AI means that it predicts the most likely answer based on the data it’s been trained on. This can lead to different but equally confident answers to the same prompt. When it comes to drug dosing, doctors need to know that the dosing recommendations AI generates are consistently accurate.

Building on Doximity’s existing work around AI safety, DoseCheck adds a deterministic, rule-based verification step to all dosing recommendations in Doximity Ask, Doximity’s clinical decision making support tool. By checking against FDA labeling and professional guidelines, DoseCheck increases accuracy to more than 99%.

Addressing an industry-wide challenge

Drug dosing accuracy is a challenge for any platform using AI to make recommendations to doctors. Doximity tested nine widely used AI models with more than 8,000 dosing questions based on real physician queries. At least 2.3% of dosing claims made by these models were wrong, and 43.8% of detected errors were serious or potentially lethal.

“AI is probabilistic. Drug dosing can’t be,” said Dr. Louis-Antoine Mullie, Chief AI Researcher at Doximity. “DoseCheck doesn’t ask a language model to grade its own homework. It checks dosing claims against a structured, authoritative database, so physicians get the same verified dosing answer every time.”

Common sources of errors identified in the analysis included:

  • Recently approved drugs: AI models need time to train on new drugs, meaning LLMs were less accurate on dosing newer drugs.
  • Failure to adapt dosing to a patient’s specific characteristics, including things like kidney function, age, weight, medical history.
  • Incorrect units, decimal point placement, and confusing drugs with similar names.

DoseCheck is free and has been rolled out to all Doximity Ask users across mobile and desktop.

This latest launch builds on Doximity’s existing work to increase safety for patients. Doximity’s PeerCheck program features more than 12,000 cited physician experts evaluating and improving Doximity Ask outputs, and Doximity Ask ranked top among U.S. clinical AI models in the NOHARM study from researchers at Stanford and Harvard.

Doximity’s membership includes more than 85% of all U.S. doctors, and its Clinical AI Suite, including Ask, has been deployed across more than 165 health systems, including 10 of the nation's top 20 hospitals.

To learn more about Doximity Ask, visit www.doximity.com .

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians. With AI-powered clinical reference and search capabilities, Doximity helps doctors access trusted, peer-reviewed information and medical literature. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

Media Contact
Richard George
[email protected]

Investor Contact
Perry Gold
[email protected]

Source: Doximity

View All News

Doximity logo

Follow us

Links

IR Contact

[email protected]

Email Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Doximity, we promise to treat your data with respect and in accordance with the terms of our Privacy Policy . You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Doximity to send you the requested Investor Email Alert updates.

* Required

Email Address * Mailing Lists *

News
Events & Presentations
Quarterly Reports
Annual Reports
SEC Filings
End of Day Stock Quote

Submit Submit

Unsubscribe

Email Alert Sign Up Confirmation

© 2026 Doximity, Inc. - All rights reserved

Powered By Q4 Inc. 5.191.0.1 (opens in new window)

10/20/2026

Physicians can see Doximity Ask's AI-generated answer in addition to expert-written content from UpToDate

SAN FRANCISCO & WALTHAM, Mass.--(BUSINESS WIRE)-- Doximity (NYSE: DOCS), the leading digital platform for U.S. medical professionals, and Wolters Kluwer Health , today announced that UpToDate ’s trusted, evidence-based, clinical content will be accessible directly within Doximity’s fast-growing AI clinical decision support tool, Ask .

UpToDate is coming to Doximity Ask

UpToDate is coming to Doximity Ask

In the coming weeks, clinicians at health systems using Doximity and UpToDate will see answers, based on content from UpToDate’s 13,000 topics and best practice guides, in addition to Doximity’s Ask answer. As one of the most widely used clinical decision support resources globally, UpToDate helps clinicians make confident decisions every day.

Nearly one in four medical questions can’t be answered by available research. Doctors treating the patient in front of them can’t wait for the evidence to catch up. In those moments, they may turn to the real-life experience of their peers, with UpToDate drawing on 7,600 expert clinicians, editors, and peer reviewers who regularly review clinical, drug, and patient content.

"Doctors know the value of a second opinion," said Jeff Tangney, CEO of Doximity. "With UpToDate available inside Doximity Ask, they can now get one instantly, from thousands of their peers, without leaving their workflow. Users can have both convenience and confidence."

“Trust in clinical AI starts with the intelligence behind the answer. UpToDate combines the latest evidence with expert judgment, peer review, and a rigorous editorial process designed to keep pace with evolving medicine,” said Yaw Fellin , Senior Vice President and General Manager, Clinical Decision Support and Provider Solutions at Wolters Kluwer Health. “Bringing that clinical intelligence into Doximity Ask gives clinicians access to trusted, cited answers within a workflow they already use at the point of care.”

In July, Doximity Ask was ranked top among U.S. clinical AI models in the NOHARM study from researchers at Stanford and Harvard.

“The number of cases for which clinical research has no direct answer would surprise you,” said Nicholas Perkins, DO, MBA, Chief Clinical Analytics Officer at Prisma Health. “Clinicians rely on trusted resources like UpToDate to support clinical decision-making when evidence is scarce. The ability to access it right within Doximity Ask has the potential to save doctors time so they can focus on helping patients."

Bridging the Medical Knowledge Gap at the Speed of AI

Doctors face an overwhelming and constantly evolving body of medical research that needs to be communicated with clear, actionable clinical guidance at the point of care.

Doximity’s membership includes more than 85% of all U.S. doctors, and its Clinical AI Suite, including Ask, has been deployed across more than 165 health systems, including 10 of the nation's top 20 hospitals. In addition, Doximity’s PeerCheck™ program features more than 12,000 cited physician experts evaluating and improving Doximity Ask outputs.

About Doximity

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians. With AI-powered clinical reference and search capabilities, Doximity helps doctors access trusted, peer-reviewed information and medical literature. Doximity's mission is to help doctors be more productive so they can provide better care for their patients.

About Wolters Kluwer

Wolters Kluwer (EURONEXT: WKL) is a global leader in information solutions, software and services for professionals in healthcare; tax and accounting; financial and corporate compliance; legal and regulatory; corporate performance and ESG. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with technology and services. Wolters Kluwer reported 2025 annual revenues of €6.1 billion. The group serves customers in over 180 countries, maintains operations in over 40 countries, and employs approximately 21,100 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands.

Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt (ADR) program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

Prompts

Doximity, Inc. (ticker DOCS), listed in United States.

ETFs Holding Doximity, Inc.

ETF Weight in ETF Shares Market value As of
SMLL 3.40% 13,944 $ 464.893K Nov 13, 2026
LSEQ 2.00% 10,255 $ 341.902K Nov 13, 2026
LGHT 1.62% 1,934 $ 40.111K Jun 30, 2026
TMAT 0.75% 84,832 $ 1.774M Jul 31, 2026
AFMC 0.48% 38,685 $ 1.268M Nov 16, 2026
BTAL short -0.39% -53,636 $ -1.112M Jun 30, 2026
SQLV 0.30% 4,133 $ 85.718K Jun 30, 2026
ESUM 0.18% 15,942 $ 333.347K Jul 31, 2026
AVSC 0.13% 131,486 $ 4.309M Nov 16, 2026
ESSC 0.10% 1,770 $ 37.011K Jul 31, 2026
JMEE 0.09% 84,581 $ 2.631M Nov 17, 2026
MKTN 0.08% 3,998 $ 82.919K Jun 30, 2026
WSGE 0.04% 706 $ 21.964K Nov 18, 2026
JSTC 0.03% 3,009 $ 98.605K Nov 17, 2026
SMDX 0.03% 1,141 $ 37.391K Nov 17, 2026
VFQY 0.02% 3,920 $ 104.703K Aug 31, 2026
RILA 0.02% 446 $ 9,325.86 Jul 31, 2026
AVUS 0.01% 24,466 $ 801.751K Nov 16, 2026
ENHU 0.01% 17 $ 557.09 Nov 16, 2026
DFAC 0.01% 195,080 $ 6.477M Nov 12, 2026
DCOR 0.01% 81,546 $ 2.707M Nov 12, 2026
DFSU 0.00% 3,539 $ 117.495K Nov 12, 2026
DFUS 0.00% 23,098 $ 766.854K Nov 12, 2026
DFAU 0.00% 10,812 $ 358.958K Nov 12, 2026
DXUV 0.00% 4,141 $ 137.481K Nov 12, 2026
MSLC 0.00% 2,885 $ 77.058K Aug 31, 2026
EBI 0.00% 32 $ 854.72 Aug 31, 2026
FMDE 0.00% 45 $ 933.30 Jun 30, 2026
AVSU 0.00% 434 $ 14.222K Nov 16, 2026
IALT 0.00% 301 $ 9,863.77 Nov 16, 2026
GVLU 0.00% 2 $ 65.54 Nov 17, 2026